Treatment-monitoring research · Chennai, India

See how cancer changes during treatment.

MIOPC™ is being developed to enrich, enumerate and image circulating tumour cells from serial blood samples—supporting research into treatment response and personalised cancer care.

Research use only · Clinical validation ongoing

Conceptual visual of tumour cells moving through a microfluidic channel
Concept visualisation of microfluidic CTC enrichmentNot clinical evidence
1.56Mestimated new cancer cases in India
901,828estimated cancer deaths
3.32Mpeople living within five years of diagnosis
237,231estimated new breast cancer cases

India estimates, 2024 · IARC GLOBOCAN

Conceptual sequence showing changing circulating tumour cell observations over time
Serial observation conceptIllustrative

After diagnosis

The question changes: is treatment working?

Imaging, pathology and clinical assessment remain essential. We are exploring whether CTCs—rare cancer cells shed into the bloodstream—can add a repeatable, cell-level research signal between standard evaluations.

01

Repeat sampling

Study change across treatment timepoints using a blood-based workflow.

02

Cell-level imaging

Preserve visual information for enumeration and downstream research.

03

Longitudinal comparison

Correlate CTC trends with established clinical findings—not replace them.

Why monitor CTCs →

A research signal from the bloodstream

From one sample to a longitudinal view.

A CTC is a cancer cell found in the blood after separating from a primary or metastatic tumour. Serial CTC research can observe how counts and cellular features change over time.

01

Baseline

Collect a pretreatment research sample.

02

Follow-up

Repeat at defined treatment timepoints.

03

Enrich

Isolate rare cells using a microfluidic workflow.

04

Image

Enumerate and retain cell-level observations.

05

Correlate

Compare trends with clinical and imaging data.

MIOPC™ workflow

Four functions. One research platform.

The planned system brings sample handling, enrichment and observation into a compact microfluidic workflow.

01

Interaction

Guide the sample through controlled microfluidic paths.

02

Incubation

Support defined reagent–cell interaction conditions.

03

Isolation

Enrich target cell populations from a complex sample.

04

Identification

Enable imaging and enumeration for research analysis.

Preliminary analytical evidence

Measured recovery in controlled spiking studies.

Early immunomagnetic experiments provide a starting point for iteration. They are not measures of clinical sensitivity or patient outcomes.

81.8%MCF-7 recovery · 818 ± 28 of 1,000 spiked cells
89.3%MDA-MB-231 recovery · 893 ± 32 of 1,000 spiked cells
Acrylic microfluidic chip prototypes fabricated for laboratory testing
Acrylic microfluidic prototypesFabrication service

Microfluidic portfolio · fabrication service

From a research need to a measurable prototype.

We fabricate acrylic-based microfluidic devices that translate research and laboratory needs into practical prototypes for testing, measurement and iteration.

Explore our microfluidic chip services →

Do you have a research need we can turn into a working microfluidic prototype?

Explore our chip formats and custom acrylic fabrication service.

View microfluidic chips